Reversing oncogenic transformation with iron chelation

// Gina Abdelaal 1 and Stephany Veuger Department of Applied Sciences, Faculty Health Life Northumbria University, Newcastle upon Tyne, UK Correspondence to: Abdelaal, email: [email protected] Keywords: iron chelator; oncogenesis; selective cytotoxicity; hallmarks cancer; NDRG1 Received: September 29, 2020     Accepted: December 16, Published: January 19, 2021 Copyright: © Veuger. This is an open access article distributed under the terms Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, reproduction in any medium, provided original author source are credited. ABSTRACT Cancer cells accumulate to supplement their aberrant growth metabolism. Depleting by chelators has been shown be selectively cytotoxic cancer vitro vivo . Iron effective at combating a range cancers including those difficult treat such as androgen insensitive prostate stem cells. review will evaluate impact chelation on cell survival underlying mechanisms action. A plethora studies have can reverse some major enabling characteristics cancer. inhibit signalling pathways that drive proliferation, migration metastasis well return tumour suppressive signalling. In addition this, stimulate apoptotic ER stress inducing death even lacking functional p53 gene. sensitise PARP inhibitors through mimicking BRCAness; feature trademark genomic instability. target metabolism, attenuating oxidative phosphorylation glycolysis. Moreover, may oncogenic transformation. therefore represent promising mode therapy.